Literature DB >> 728866

Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.

S E Krown, E Y Hilal, C M Pinsky, Y Hirshaut, H J Wanebo, J A Hansen, A G Huvos, H F Oettgen.   

Abstract

Twenty-two patients with cutaneous metastases of malignant melanoma were treated with intralesional injections of the methanol extraction residue of bacillus Calmette-Guerin (MER). The local reaction consisted of erythema and pustule formation followed by ulceration and tumor necrosis. Side effects included fever, chills, headache and malaise in the majority of patients; nausea, vomiting, cyanosis and hypotension occurred infrequently. Hypersensitivity reactions were not observed. Temporary abnormalities in liver function were seen in 11 of 19 patients tested. Reversible lymphopenia and thrombocytopenia developed in 7 of 17 and 7 of 18 patients, respectively. Immune function, as measured by skin tests for delayed hypersensitivity and the in vitro response of isolated lymphocytes to mitogens and microbial antigens, was not influenced by treatment with MER. Transient increases were observed in total hemolytic complement, complement components and the reduction of nitroblue-tetrazolium by neutrophils. Eight of eighteen evaluable patients showed a complete disappearance of all injected lesions. We conclude that intratumoral injection of MER is effective treatment for cutaneous metastases of malignant melanoma, with a complete response rate comparable to that observed after intralesional injection of BCG.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 728866     DOI: 10.1002/1097-0142(197812)42:6<2648::aid-cncr2820420621>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Evaluation of therapy with methanol extraction residue of BCG (MER).

Authors:  E M Hersh; J Quesada; S G Murphy; J U Gutterman; R D Hutchins
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

2.  [Intratumor immunotherapy with BCG cell wall preparations: development of a new therapy approach for head-neck tumors].

Authors:  J Bier; S Kleinschuster; H Bier; H Rapp
Journal:  Arch Otorhinolaryngol       Date:  1982

3.  Intratumoral immunization: a new paradigm for cancer therapy.

Authors:  Aurélien Marabelle; Holbrook Kohrt; Christophe Caux; Ronald Levy
Journal:  Clin Cancer Res       Date:  2014-04-01       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.